Image
illustration
Growth & Buyout News

Latest News from SEQENS

Wednesday 23 March, 2022
Body

March 17th  |  SEQENS is investing €100 million to build a paracetamol active ingredient production unit in Roussillon, France, which will produce 10,000 tons per year from 2023. This investment is partly financed by the France Recovery Plan (“France Relance”).

March 21st  |  SEQENS makes multi-million dollar Investment in its U.S. R and D Laboratory located in Devens, Mass. This investment signals major commitment to U.S. market and builds on merger with CDMO Wavelength Pharmaceuticals. The new facility will enhance Seqens’ capabilities in the development and production of Active Pharmaceutical Ingredients (APIs) and active delivery systems (Lipids and Polymers) development.

March 23rd  |  SEQENS celebrates a new milestone in the joint cooperation with the Rondol Group to improve bioavailability of selected molecules with the successful installation of their first GMP vertical extrusion line at the SEQENS Lab in Porcheville, France. Seqens brings its skills and expertise as a global leader in small molecules APIs while Rondol brings its expertise in the development and continuous improvement of drug dosage extrusion technologies.

Content